ARAY Accuray Incorporated - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ARAY Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Medical Devices
Current Price
Live
$0.49
Analyst Target
$2.52
+415.0%
Upside
52W High
$2.1
52W Low
$0.48
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
ARAY's Piotroski F-Score of 4/9 indicates weak financial health, falling into the 'Weak' range, with no Altman Z-Score available to assess bankruptcy risk. The company exhibits negative ROE (-70.32%) and ROA (-1.18%), high debt/equity (2.90), and a negative profit margin (-8.15%), despite modest revenue growth (16.80% YoY). The stock trades at a deeply discounted Price/Sales (0.13) and Price/Book (1.09), but this is likely due to persistent losses and deteriorating earnings quality. Analysts' target price of $2.52 suggests optimism, but the 5-year price decline of -90.1% and erratic earnings surprises underscore significant execution and profitability challenges.
Key Strengths
16.80% year-over-year revenue growth indicates top-line expansion in a competitive medical device sector
Positive operating margin (3.73%) suggests some operational efficiency despite net losses
Gross margin of 27.85% reflects decent pricing power and cost control in production
Insider sentiment at 60/100 indicates moderate confidence from internal stakeholders
Price/Sales of 0.13 implies deep undervaluation relative to peers, potentially offering a margin of safety
Key Risks
Piotroski F-Score of 4/9 signals weak financial health, with multiple red flags in profitability and leverage
Negative ROE (-70.32%) and ROA (-1.18%) indicate poor capital efficiency and declining shareholder value
Debt/Equity ratio of 2.90 is extremely high, suggesting over-leveraged balance sheet and refinancing risk
Earnings volatility with average surprise of -79.85% over last 4 quarters and multiple negative EPS beats
No free cash flow or operating cash flow data available, raising concerns about liquidity and sustainability
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare ARAY against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning ARAY from our newsroom.
Newest → oldest
No matching news yet.